The diagnostic value of golgi protien-73 and DICKKOPF-1 in hepatocellular carcinoma

El-Zefzafy, Wafaa M.; Hussien, Magda; Mohmmed, Zakia Abu Zahab; Elbaky, Nashwa Mohammed Abd

doi:10.1080/15321819.2020.1844750

Cited by 11 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DKK-1 shows higher efficacy for detecting HCC than AFP in phase 4 trials ( 206 – 208 ), but midkine is more precise than DKK-1 in cirrhotic HCV patients ( 209 ). A combination of Golgi protein 73, AFP, and Dickkopf-1 increases the sensitivity and specificity of HCC detection ( 210 ).…”

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide. Management of HCC depends on reliable biomarkers for screening, diagnosis, and monitoring of the disease, as well as predicting response towards therapy and safety. To date, imaging has been the established standard technique in the diagnosis and follow-up of HCC. However, imaging techniques have their limitations, especially in the early detection of HCC. Therefore, there is an urgent need for reliable, non/minimal invasive biomarkers. To date, alpha-fetoprotein (AFP) is the only serum biomarker used in clinical practice for the management of HCC. However, AFP is of relatively rather low quality in terms of specificity and sensitivity. Liquid biopsies as a source for biomarkers have become the focus of clinical research. Our review highlights alternative biomarkers derived from liquid biopsies, including circulating tumor cells, proteins, circulating nucleic acids, and exosomes, and their potential for clinical application. Using defined combinations of different biomarkers will open new perspectives for diagnosing, treating, and monitoring HCC.

show abstract

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous studies have identified biomarkers, such as Alphafetoprotein (AFP), apyrimidinic endodeoxyribonuclease 1 (APEX1), glypican 3 (GPC3), Golgi protein-73 (GP73), and Dickkopf-1 (DKK1), for HCC diagnosis (9)(10)(11)(12)(13). Among them, AFP is considered the gold standard diagnostic marker for HCC.…”

Section: Introductionmentioning

confidence: 99%

Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma

Sun

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common types of cancer. The novel sensitive biomarkers and therapeutic targets are urgently needed for the early diagnosis of HCC and improvement of clinical outcomes. Glia maturation factor-β (GMFB) is a growth and differentiation factor for both glia and neurons and has been found to be tightly involved in inflammation and neurodegeneration conditions. In our study, the expression level of GMFB was significantly up-regulated in patients with HCC and positively co-expression with tumor node metastases (TNM) stage and histopathological grade of HCC. The high expression level of GMFB was remarkably associated with poor overall survival, which mainly occurred in males rather than females. Multivariate analysis revealed GMFB to be an independent prognostic factor for overall survival in patients with HCC. Results of Gene Ontology (GO) and KEGG pathways analysis showed that down-regulation of pathways related to protein translation and mitochondria function were enriched. Protein-protein interaction analysis revealed the central role of mitochondria protein in HCC. The downregulation of genes involved in glycolysis and gluconeogenesis was observed among the co-expression genes of GMFB. Knockdown of GMFB in Hep3B significantly inhibited proliferation, migration, and invasion of Hep3B cells, and also downregulated the expression levels of some of metal matrix proteinase (MMP), increased mtDNA copy number and loss of mitochondrial transmembrane potential. GMFB influences the malignancy rate of HCC possibly through regulation of the expression of MMPs, mtDNA function and glycolysis. We proposed that GMFB was a promising HCC diagnostic and prognostic biomarker and therapeutic target in HCC.

show abstract

“…The two-marker panel of GP73 and DKK-1 demonstrated the highest specificity and sensitivity [62]. Similarly, a 2021 Egyptian study found that using GP73, DKK-1, and α-FP together improved the sensitivity and specificity for the diagnosis of HCC compared to using each one separately [86]. Finally, according to a 2021 meta-analysis, the sum of sensitivity and specificity of α-FP with GP73 was 1.76 (p = 0.0001), the best among all panels including multiple biomarkers.…”

Section: Combination Of Hcc Biomarkersmentioning

confidence: 94%

“…Dickkopf-1 (DKK1) is a member of the DKK Family and a secretory glycoprotein [85], that is tumour-specific and highly expressed in adult liver and other gastrointestinal neoplasms [86].…”

Section: Opnmentioning

confidence: 99%

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Shahini

Pasculli

Solimando

et al. 2023

IJMS

View full text Add to dashboard Cite

The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality rate is increasing globally. The overall 5-year survival of patients with liver cancer is currently 10–20%. Moreover, because early diagnosis can significantly improve prognosis, which is highly correlated with tumor stage, early detection of HCC is critical. International guidelines advise using α-FP biomarker with/without ultrasonography for HCC surveillance in patients with advanced liver disease. However, traditional biomarkers are sub-optimal for risk stratification of HCC development in high-risk populations, early diagnosis, prognostication, and treatment response prediction. Since about 20% of HCCs do not produce α-FP due to its biological diversity, combining α-FP with novel biomarkers can enhance HCC detection sensitivity. There is a chance to offer promising cancer management methods in high-risk populations by utilizing HCC screening strategies derived from new tumor biomarkers and prognostic scores created by combining biomarkers with distinct clinical parameters. Despite numerous efforts to identify molecules as potential biomarkers, there is no single ideal marker in HCC. When combined with other clinical parameters, the detection of some biomarkers has higher sensitivity and specificity in comparison with a single biomarker. Therefore, newer biomarkers and models, such as the Lens culinaris agglutinin-reactive fraction of Alpha-fetoprotein (α-FP), α-FP-L3, Des-γ-carboxy-prothrombin (DCP or PIVKA-II), and the GALAD score, are being used more frequently in the diagnosis and prognosis of HCC. Notably, the GALAD algorithm was effective in HCC prevention, particularly for cirrhotic patients, regardless of the cause of their liver disease. Although the role of these biomarkers in surveillance is still being researched, they may provide a more practical alternative to traditional imaging-based surveillance. Finally, looking for new diagnostic/surveillance tools may help improve patients’ survival. This review discusses the current roles of the most used biomarkers and prognostic scores that may aid in the clinical management of HCC patients.

show abstract

The diagnostic value of golgi protien-73 and DICKKOPF-1 in hepatocellular carcinoma

Cited by 11 publications

References 25 publications

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Contact Info

Product

Resources

About